Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02530047 · ClinicalTrials.gov registry record · Phase 1

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

A Phase 1 study of Ovarian Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT02530047: Completed Phase 1 study of Ovarian Cancer, sponsored by M.D. Anderson Cancer Center.

NCT02530047 is a Phase 1 study of Ovarian Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02530047, a Phase 1 study of Ovarian Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of human mesenchymal stem cells with interferon beta (MSC-INFb) that can be given to patients with ovarian cancer and to test the safety of the MSC-INFb. This is an investigational study. MSC-INFb infusions for ovarian cancer is investigational. Up to 21 patients will take part in this study. All will be enrolled at MD Anderson.

Primary Outcome

Maximum Tolerated Dose (MTD) is dose with posterior probability of dose limiting toxicities (DLTs) nearest to 30%, provided the lower bound of the 90% credible interval for the posterior probability of DLT does not exceed 30%. Dose limiting toxicities (DLTs) are those adverse events of grade 3 or 4 that occur up to 1 week after the last dose.

Conditions Studied

Ovarian Cancer

Interventions

  • BEHAVIORAL Questionnaires
  • GENETIC MSC-INFβ

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2016-05-16
Est. Completion 2019-06-13
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT02530047 record still lists

NCT02530047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.

NCT02530047 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02530047 about?

NCT02530047 is a clinical study titled "Mesenchymal Stem Cells (MSC) for Ovarian Cancer". The goal of this clinical research study is to find the highest tolerable dose of human mesenchymal stem cells with interferon beta (MSC-INFb) that can be given to patients with ovarian cancer and to test the safety of the MSC-INFb. This is an investigational study. MSC-INFb infusions for ovarian c...

What is the current status of trial NCT02530047?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-05-16. Estimated completion is 2019-06-13.

What conditions does trial NCT02530047 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT02530047?

The interventions under investigation include: Questionnaires (BEHAVIORAL), MSC-INFβ (GENETIC).

Who is sponsoring clinical trial NCT02530047?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02530047 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02530047's enrollment target sits among peer trials

5 318th of 322 higher than 3 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02530047, the US trial registry maintained by the National Library of Medicine. NCT02530047 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.